The role of co-morbidity in the selection of antidiabetic pharmacotherapy in type-2 diabetes

Cardiovascular Diabetology

Volumn 12, Issue 1, 2013, Pages

  Tschöpe, Diethelm ^a   Hanefeld, Markolf ^b   Meier, Juris J ^c   Gitt, Anselm K ^d   Halle, Martin ^e,f   Bramlage, Peter ^g   Schumm Draeger, Petra Maria ^h  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Study Centre Professor Hanefeld GWT TUD   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

^d Institut fur Herzinfarktforschung Ludwigshafen   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^g Institut fur Pharmakologie und Praventive Medizin   (Germany)

^h Chirurgische Klinik Munchen Bogenhausen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; INSULIN; INSULIN DERIVATIVE; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; NATEGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; STEROID; SULFONYLUREA; TOLBUTAMIDE; VILDAGLIPTIN;

ALBUMINURIA; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL PRACTICE; COMORBIDITY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DRUG COST; DRUG EFFICACY; DRUG MEGADOSE; HEART FAILURE; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; HYPOGLYCEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIFESTYLE MODIFICATION; LIVER DYSFUNCTION; LIVER FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT PREFERENCE; PROGNOSIS; REVIEW; SIDE EFFECT; SYSTOLIC HEART FAILURE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; LIVER FAILURE; PRACTICE GUIDELINE;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HEART FAILURE; HEPATIC INSUFFICIENCY; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; OBESITY; PRACTICE GUIDELINES AS TOPIC; RENAL INSUFFICIENCY, CHRONIC;

EID: 84875917880     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-12-62     Document Type: Review

References (84)

1. American Diabetes Association Standards of medical care in diabetes-2013. Diabetes Care 2013, 36(Suppl 1):S11-S66. American Diabetes Association.
2. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55(6):1577-1596. 10.1007/s00125-012-2534-0, 22526604.
3. Wermeling PR, Gorter KJ, van Stel HF, Rutten GE. Both cardiovascular and non-cardiovascular comorbidity are related to health status in well-controlled type 2 diabetes patients: a cross-sectional analysis. Cardiovasc Diabetol 2012, 11:121. 10.1186/1475-2840-11-121, 3508839, 23039172.
4. Wasem J, Bramlage P, Gitt AK, Binz C, Krekler M, Deeg E, Tschope D. Co-morbidity but not dysglycaemia reduces quality of life in patients with type-2 diabetes treated with oral mono- or dual combination therapy - an analysis of the DiaRegis registry. Cardiovasc Diabetol 2013, 12(1):47. 10.1186/1475-2840-12-47, 3606825, 23510200.
5. United Kingdom Prospective Diabetes Study Group United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998, 128(3):165-175. United Kingdom Prospective Diabetes Study Group.
6. Goldstein BJ, Feinglos MN, Lunceford JK, Johnson J, Williams-Herman DE. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30(8):1979-1987. 10.2337/dc07-0627, 17485570.
7. Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ. Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12(3):252-261. 10.1111/j.1463-1326.2009.01187.x, 20070351.
8. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008, 10(10):959-969. 10.1111/j.1463-1326.2007.00839.x, 18201203.
9. Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron MA. PRESERVE-beta: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 2005, 28(9):2093-2099. 10.2337/diacare.28.9.2093, 16123472.
10. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999, 281(21):2005-2012. 10.1001/jama.281.21.2005, 10359389.
11. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA 2010, 303(14):1410-1418. 10.1001/jama.2010.405, 20388897.
12. Meneghini LF, Orozco-Beltran D, Khunti K, Caputo S, Damci T, Liebl A, Ross SA. Weight beneficial treatments for type 2 diabetes. J Clin Endocrinol Metab 2011, 96(11):3337-3353. 10.1210/jc.2011-1074, 21900381.
13. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010, 86(1):44-57. 10.1159/000314690, 20616619.
14. Gross JL, Kramer CK, Leitao CB, Hawkins N, Viana LV, Schaan BD, Pinto LC, Rodrigues TC, Azevedo MJ. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis. Ann Intern Med 2011, 154(10):672-679. 10.7326/0003-4819-154-10-201105170-00007, 21576535.
15. Parving HH, Lewis JB, Ravid M, Remuzzi G, Hunsicker LG. Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int 2006, 69(11):2057-2063. 10.1038/sj.ki.5000377, 16612330.
16. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169. 10.1136/bmj.d4169, 3144314, 21791495.
17. Hattori S. Sitagliptin reduces albuminuria in patients with type 2 diabetes. Endocr J 2011, 58(1):69-73. 10.1507/endocrj.K10E-382, 21206136.
18. Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE. Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 2011, 6(5):1032-1040. 10.2215/CJN.09291010, 3087768, 21454723.
19. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003, 17(1):7-12. 10.1038/sj.jhh.1001444, 12571611.
20. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008, 358(6):580-591. 10.1056/NEJMoa0706245, 18256393.
21. Centers for Disease Control and Prevention 2011 National diabetes fact sheet: National estimates and general information on diabetes and prediabetes in the United States http://www.cdc.gov/diabetes/pubs/factsheet11.htm, Centers for Disease Control and Prevention.
22. Shurraw S, Hemmelgarn B, Lin M, Majumdar SR, Klarenbach S, Manns B, Bello A, James M, Turin TC, Tonelli M. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011, 171(21):1920-1927. 10.1001/archinternmed.2011.537, 22123800.
23. Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011, 34(6):1431-1437. 10.2337/dc10-2361, 3114336, 21617112.
24. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, 4. CD002967.
25. Rabkin R, Ryan MP, Duckworth WC. The renal metabolism of insulin. Diabetologia 1984, 27(3):351-357. 10.1007/BF00304849, 6389240.
26. Muhlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type I diabetic patients with impaired kidney function. Diabetes Care 1991, 14(4):344-346. 10.2337/diacare.14.4.344, 2060440.
27. Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet 2012, 51(8):501-514.
28. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI. Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 2003, 43(3):252-259. 10.1177/0091270002250602, 12638393.
29. Williams R, Airey M, Baxter H, Forrester J, Kennedy-Martin T, Girach A. Epidemiology of diabetic retinopathy and macular oedema: a systematic review. Eye (Lond) 2004, 18(10):963-983.
30. Ling R, Ramsewak V, Taylor D, Jacob J. Longitudinal study of a cohort of people with diabetes screened by the Exeter Diabetic Retinopathy Screening Programme. Eye (Lond) 2002, 16(2):140-145.
31. Chen E, Looman M, Laouri M, Gallagher M, Van Nuys K, Lakdawalla D, Fortuny J. Burden of illness of diabetic macular edema: literature review. Curr Med Res Opin 2010, 26(7):1587-1597. 10.1185/03007995.2010.482503, 20429823.
32. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359(15):1577-1589. 10.1056/NEJMoa0806470, 18784090.
33. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World J Diabetes 2011, 2(6):98-104. 10.4239/wjd.v2.i6.98, 3158878, 21860693.
34. Anfossi G, Russo I, Doronzo G, Trovati M. Relevance of the vascular effects of insulin in the rationale of its therapeutical use. Cardiovasc Hematol Disord Drug Targets 2007, 7(4):228-249. 10.2174/187152907782793581, 18220724.
35. Fong DS, Contreras R. Glitazone use associated with diabetic macular edema. Am J Ophthalmol 2009, 147(4):583-586. e581, 10.1016/j.ajo.2008.10.016, 19181303.
36. Ambrosius WT, Danis RP, Goff DC, Greven CM, Gerstein HC, Cohen RM, Riddle MC, Miller ME, Buse JB, Bonds DE, Peterson KA, Rosenberg YD, Perdue LH, Esser BA, Seaquist LA, Felicetta JV, Chew EY. Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy. Arch Ophthalmol 2010, 128(3):312-318. 10.1001/archophthalmol.2009.310, 3010554, 20212201.
37. Fisman EZ, Tenenbaum A. A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovasc Diabetol 2009, 8:38. 10.1186/1475-2840-8-38, 2723076, 19619327.
38. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998, 338(4):265-266. 10.1056/NEJM199801223380415, 9441244.
39. Fisman EZ, Tenenbaum A, Benderly M, Goldbourt U, Behar S, Motro M. Antihyperglycemic treatment in diabetics with coronary disease: increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999, 91(3):195-202. 10.1159/000006909, 10516414.
40. Horsdal HT, Johnsen SP, Sondergaard F, Rungby J. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: a nationwide follow-up study. Diabetologia 2008, 51(4):567-574. 10.1007/s00125-008-0947-6, 18283428.
41. Monami M, Marchionni N, Masotti G, Mannucci E. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. Int J Cardiol 2008, 126(2):247-251. 10.1016/j.ijcard.2007.03.135, 17512619.
42. Boussageon R, Supper I, Bejan-Angoulvant T, Kellou N, Cucherat M, Boissel JP, Kassai B, Moreau A, Gueyffier F, Cornu C. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012, 9(4):e1001204. 10.1371/journal.pmed.1001204, 3323508, 22509138.
43. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2004, 164(18):2005-2011. 10.1001/archinte.164.18.2005, 15477435.
44. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A, Wedel H, Welin L. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol 1995, 26(1):57-65. 10.1016/0735-1097(95)00126-K, 7797776.
45. Malmberg K, Ryden L, Wedel H, Birkeland K, Bootsma A, Dickstein K, Efendic S, Fisher M, Hamsten A, Herlitz J, Hildebrandt P, MacLeod K, Laakso M, Torp-Pedersen C, Waldenstrom A. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005, 26(7):650-661. 10.1093/eurheartj/ehi199, 15728645.
46. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359(9323):2072-2077. 10.1016/S0140-6736(02)08905-5, 12086760.
47. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Supp):789-830.
48. Horsdal HT, Johnsen SP, Sondergaard F, Jacobsen J, Thomsen RW, Schmitz O, Sorensen HT, Rungby J. Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 2009, 25(6):515-522. 10.1002/dmrr.971, 19459168.
49. Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbol EL, Kober L, Norgaard ML, Madsen M, Hansen PR, Torp-Pedersen C. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32(15):1900-1908. 10.1093/eurheartj/ehr077, 21471135.
50. Horsdal HT, Mehnert F, Rungby J, Johnsen SP. Type of preadmission antidiabetic treatment and outcome among patients with ischemic stroke: a nationwide follow-up study. J Stroke Cerebrovasc Dis 2012, 21(8):717-725. 10.1016/j.jstrokecerebrovasdis.2011.03.007, 21536457.
51. Blankenship D, Niemi J, Hilow E, Karl M, Sundararajan S. Oral pioglitazone reduces infarction volume and improves neurologic function following MCAO in rats. Adv Exp Med Biol 2011, 701:157-162. 10.1007/978-1-4419-7756-4_22, 21445783.
52. Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C, Lyden PD, Morgenstern LB, Qureshi AI, Rosenwasser RH, Scott PA, Wijdicks EF. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007, 38(5):1655-1711. 10.1161/STROKEAHA.107.181486, 17431204.
53. Fuentes B, Ortega-Casarrubios MA, Sanjose B, Castillo J, Leira R, Serena J, Vivancos J, Davalos A, Gil-Nunez A, Egido J, Diez-Tejedor E. Persistent hyperglycemia >155 mg/dL in acute ischemic stroke patients: how well are we correcting it?: implications for outcome. Stroke 2010, 41(10):2362-2365. 10.1161/STROKEAHA.110.591529, 20724713.
54. Gray CS, Hildreth AJ, Sandercock PA, O'Connell JE, Johnston DE, Cartlidge NE, Bamford JM, James OF, Alberti KG. Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007, 6(5):397-406. 10.1016/S1474-4422(07)70080-7, 17434094.
55. Leung AA, Eurich DT, Lamb DA, Majumdar SR, Johnson JA, Blackburn DF, McAlister FA. Risk of heart failure in patients with recent-onset type 2 diabetes: population-based cohort study. J Card Fail 2009, 15(2):152-157. 10.1016/j.cardfail.2008.10.004, 19254675.
56. Eurich DT, McAlister FA, Blackburn DF, Majumdar SR, Tsuyuki RT, Varney J, Johnson JA. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 2007, 335(7618):497. 10.1136/bmj.39314.620174.80, 1971204, 17761999.
57. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352(9131):837-853. UK Prospective Diabetes Study (UKPDS) Group.
58. Andersson C, Olesen JB, Hansen PR, Weeke P, Norgaard ML, Jorgensen CH, Lange T, Abildstrom SZ, Schramm TK, Vaag A, Kober L, Torp-Pedersen C, Gislason GH. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 2010, 53(12):2546-2553. 10.1007/s00125-010-1906-6, 20838985.
59. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25(1):10-16. 10.1016/S0195-668X(03)00468-8, 14683737.
60. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005, 111(5):583-590. 10.1161/01.CIR.0000154542.13412.B1, 15699279.
61. Gupte P, Amarapurkar D, Agal S, Baijal R, Kulshrestha P, Pramanik S, Patel N, Madan A, Amarapurkar A, Hafeezunnisa. Non-alcoholic steatohepatitis in type 2 diabetes mellitus. J Gastroenterol Hepatol 2004, 19(8):854-858. 10.1111/j.1440-1746.2004.03312.x, 15242486.
62. Kutoh E. Possible metformin-induced hepatotoxicity. Am J Geriatr Pharmacother 2005, 3(4):270-273. 10.1016/j.amjopharm.2005.12.002, 16503324.
63. Khan R, Foster GR, Chowdhury TA. Managing diabetes in patients with chronic liver disease. Postgrad Med 2012, 124(4):130-137. 10.3810/pgm.2012.07.2574, 22913901.
64. Ahmed MH, Byrne CD. Current treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab 2009, 11(3):188-195. 10.1111/j.1463-1326.2008.00926.x, 18564173.
65. Garinis GA, Fruci B, Mazza A, De Siena M, Abenavoli S, Gulletta E, Ventura V, Greco M, Abenavoli L, Belfiore A. Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study. Int J Obes (Lond) 2010, 34(8):1255-1264.
66. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001, 358(9285):893-894. 10.1016/S0140-6736(01)06042-1, 11567710.
67. Migoya EM, Stevens CH, Bergman AJ, Luo WL, Lasseter KC, Dilzer SC, Davies MJ, Wagner JA, Herman GA. Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Can J Clin Pharmacol 2009, 16(1):e165-e170.
68. Nielsen LL, Okerson T, Holcombe J, Hoogwerf B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. J Diabetes Sci Technol 2008, 2(2):255-260. 2771486, 19885351.
69. Breuer TG, Meier JJ. Inpatient treatment of type 2 diabetes. Dtsch Arztebl Int 2012, 109(26):466-474. 3401956, 22833757.
70. UK Hypoglycaemia Study Group Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia 2007, 50(6):1140-1147. UK Hypoglycaemia Study Group.
71. Zoungas S, Patel A, Chalmers J, de Galan BE, Li Q, Billot L, Woodward M, Ninomiya T, Neal B, MacMahon S, Grobbee DE, Kengne AP, Marre M, Heller S. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010, 363(15):1410-1418. 10.1056/NEJMoa1003795, 20925543.
72. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355(23):2427-2443. 10.1056/NEJMoa066224, 17145742.
73. Siebenhofer A, Plank J, Berghold A, Jeitler K, Horvath K, Narath M, Gfrerer R, Pieber TR. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 2006, 2. CD003287.
74. American Diabetes Association Economic costs of diabetes in the U.S. In 2007. Diabetes Care 2008, 31(3):596-615. American Diabetes Association.
75. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000, 355(9206):773-778. 10.1016/S0140-6736(99)08415-9, 10711923.
76. Ramos M, Khalpey Z, Lipsitz S, Steinberg J, Panizales MT, Zinner M, Rogers SO. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 2008, 248(4):585-591.
77. American Diabetes Association Standards of medical care in diabetes-2007. Diabetes Care 2007, 30(Suppl 1):S4-S41. American Diabetes Association.
78. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. Crit Care Med 2009, 37(12):3001-3009. 10.1097/CCM.0b013e3181b083f7, 2905804, 19661802.
79. Clement S. Guidelines for glycemic control. Clin Cornerstone 2004, 6(2):31-39. 10.1016/S1098-3597(04)80052-8, 15628691.
80. Pozzilli P, Leslie RD, Chan J, De Fronzo R, Monnier L, Raz I, Del Prato S. The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev 2010, 26(4):239-244. 10.1002/dmrr.1092, 20503255.
81. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32(1):193-203. 10.2337/dc08-9025, 2606813, 18945920.
82. Bremer JP, Jauch-Chara K, Hallschmid M, Schmid S, Schultes B. Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 2009, 32(8):1513-1517. 10.2337/dc09-0114, 2713637, 19487634.
83. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, Howard BV, Kirkman MS, Kosiborod M, Reaven P, Sherwin RS. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009, 53(3):298-304. 10.1016/j.jacc.2008.10.008, 19147051.
84. Papa G, Fedele V, Chiavetta A, Lorenti I, Leotta C, Luca S, Rabuazzo AM, Piro S, Alagona C, Spadaro L, Purrello F, Pezzino V. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. Acta Diabetol 2008, 45(1):53-59. 10.1007/s00592-007-0023-6, 18180864.